Interferon gamma release assays in patients with respiratory isolates of non-tuberculous mycobacteria - a preliminary study

• Autorzy: Augustynowicz-Kopec E. , Siemion-Szczesniak I. , Zabost A. , Wyrostkiewicz D. , Filipczak D. , Oniszh K. , Gawryluk D. , Radzikowska E. , Korzybski D. , Szturmowicz M.
• Języki publikacji: EN

Abstrakty

EN

Interferon gamma releasing assays (IGRAs) are extensively used in the diagnosis of latent tuberculosis infections. Comparing to tuberculin skin test (TST) they lack false positive results in the populations vaccinated with BCG, and in most non-tuberculous mycobacteria (NTM) infections. Nevertheless, Mycobacterium kansasii, Mycobacterium marinum, and Mycobacterium szulgai may induce positive IGRAs due to RD1 homology with Mycobacterium tuberculosis. The aim of the study was to investigate the possible influence of NTM respiratory isolates on the results of IGRAs. 39 patients (23 females and 16 males) of median age 61 years, with negative medical history concerning tuberculosis, entered the study. Identification of NTM was performed using the niacin test and molecular method GenoType CM test (Hain Lifescience). QFT-Plus was performed in 17 patients, T-SPOT-Tb – in 23 patients. Chest X-rays and a high-resolution computed tomography of the chest have been reviewed by the experienced radiologist blinded to the results of IGRAs, in search of past tuberculosis signs. Positive IGRAs results were obtained in three out of 39 patients (8%): 22% of patients with M. kansasii isolatesand 18% of patients with radiological signs on HRCT that might be suggestive of past tuberculosis. Positive IGRAs correlated with radiological signs suggestive of past tuberculosis (r = 0.32, p = 0.04), and on the borderline with isolation of M. kansasii (r = 0.29, p = 0.06). These findings may suggest that a positive IGRAs result, in our material, could depend mostly on asymptomatic past Tb infection. The cross-reactivity of M. kansasiiisolates with IGRAs was less probable; nevertheless, it requires further investigations.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2019
• Tom: 68
• Numer: 1
• Opis fizyczny: p.15-19,ref.,

Twórcy

autor

Augustynowicz-Kopec E.

• Department of Microbiology, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Siemion-Szczesniak I.

• First Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Zabost A.

• Department of Microbiology, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Wyrostkiewicz D.

• First Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Filipczak D.

• Department of Microbiology, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Oniszh K.

• Department of Radiology and Diagnostic Imaging, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Gawryluk D.

• Third Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Radzikowska E.

• Third Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Korzybski D.

• Second Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

autor

Szturmowicz M.

• First Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

Bibliografia

• Adams LV, Waddell RD, Fordham Von Reyn C. T-SPOT. TB Test® results in adults with Mycobacterium avium complex pulmonary disease. Scand J Infect Dis. 2008;40(3):196–203. doi:10.1080/00365540701642179 Medline
• Adzic-Vukicevic T, Barac A, Blanka-Protic A, Laban-Lazovic M, Lukovic B, Skodric-Trifunovic V, Rubino S. Clinical features of infection caused by non-tuberculous mycobacteria: 7 years’ expe-rience. Infection. 2018;46(3):357–363. doi:10.1007/s15010-018-1128-2 Medline
• Bakuła Z, Kościuch J, Safianowska A, Proboszcz M, Bielecki J,van Ingen J, Krenke R, Jagielski T. Clinical, radiological and mole-cular features of Mycobacterium kansasii pulmonary disease. Respir Med. 2018;139:91–100. doi:10.1016/j.rmed.2018.05.007 Medline
• Borkowska D, Zwolska Z, Michałowska-Mitczuk D, Korze-niewska-Koseła M, Zabost A, Napiórkowska A, Kozińska M, Brzezińska S, Augustynowicz-Kopeć E. [Interferon-gamma assays T-SPOT.TB for the diagnosis of latent tuberculosis infection] (in Polish). Pneumonol Alergol Pol. 2011;79(4):264–271. Medline
• Borkowska DI, Napiórkowska AM, Brzezińska SA, Kozińska M, Zabost AT, Augustynowicz-Kopeć EM. From latent tuberculosis infection to tuberculosis. News in diagnostics (QuantiFERON-Plus). Pol J Microbiol. 2017;66(1):5–8. doi:10.5604/17331331.1234987 Medline
• Demkow U. [Interferon gamma based tests as a new tool in diag-nosis of latent tuberculosis] (in Polish). Pneumonol Alergol Pol. 2011;79(4):261–263. Medline
• European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and moni-toring in Europe 2016–2018. Stockholm (Sweden): European Centre for Disease Prevention and Control. 2018.
• Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF,et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An offi-cial ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST Medline
• Korzeniewska-Koseła M (editor). Gruźlica i choroby układu odde-chowego w Polsce w 2017 roku. Warszawa (Poland): Instytut Gruźlicyi Chorób Płuc. 2018.
• Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Lauren-son IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, et al.British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Tho-rax. 2017;72 Suppl 2:ii1–ii64. doi:10.1136/thoraxjnl-2017-210927 Medline
• Hermansen TS, Thomsen VØ, Lillebaek T, Ravn P. Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. PLoS One. 2014;9(4):e93986.doi:10.1371/journal.pone.0093986 Medline
• Hoefsloot W, van Ingen J, Andrejak C, Ängeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, et al.; Non-tuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–1613. doi:10.1183/09031936.00149212 Medline
• Klatt M, Zabost A, Augustynowcz-Kopeć E. Diagnostyka mikro-biologiczna gruźlicy z zastosowaniem testów genetycznych XPERT MTB/RIF. Zakażenia. 2015;15(6):85–92.
• Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacte-rial disease. Int J Tuberc Lung Dis. 2009;13(11):1422–1426. Medline
• Korzeniewska-Koseła M. Tuberculosis in Poland in 2015. Przegl Epidemiol. 2017;71(3):391–403. Medline
• Kuś J, Demkow U, Lewandowska K, Korzeniewska-Koseła M, Rabczenko D, Siemion-Szcześniak I, Białas-Chromiec B, Bychaw-ska M, Sapigórski P, Maciejewski J. [Prevalence of latent infection with Mycobacterium tuberculosis in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10]. Pneumonol Alergol Pol. 2011;79(6):407–418. Medline
• Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185(4):427–434. doi:10.1164/rccm.201107-1244OC Medline
• Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–976. doi:10.1164/rccm.201002-0310OC Medline
• Ra SW, Lyu J, Choi C-M, Oh Y-M, Lee S-D, Kim WS, Kim DS, Shim TS. Distinguishing tuberculosis from Mycobacterium aviumcomplex disease using an interferon-gamma release assay. Int J TubercLung Dis. 2011;15(5):635–640. doi:10.5588/ijtld.10.0485 Medline
• Sato R, Nagai H, Matsui H, Kawabe Y, Takeda K, Kawashima M, Suzuki J, Ohshima N, Masuda K, Yamane A, et al. Interferon-gamma release assays in patients with Mycobacterium kansasiipulmonary infection: A retrospective survey. J Infect. 2016;72(6):706–712. doi:10.1016/j.jinf.2016.03.011 Medline
• Słupek A, Zwolska Z, Miller M, Rowińska-Zakrzewska E. [Pul-monary mycobacteriosis-diagnostic problem and prevalence in Poland (a retrospective study)]. (in Polish). Pneumonol Alergol Pol. 1997;65(5–6):326–332. Medline
• van der Werf MJ, Ködmön C, Katalinić-Janković V, Kum-mik T, Soini H, Richter E, Papaventsis D, Tortoli E, Perrin M, van Soolingen D, et al. Inventory study of non-tuberculous myco-bacteria in the European Union. BMC Infect Dis. 2014;14(1):62–70. doi:10.1186/1471-2334-14-62 Medline
• Wang MS, Wang JL, Wang XF. The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China. BMC Pulm Med. 2016;16(1):163. doi:10.1186/s12890-016-0320-3 Medline
• Wilińska E, Oniszh K, Augustynowicz-Kopeć E, Zabost A, Fijałkowska A, Kurzyna M, Wieteska M, Torbicki A, Kuś J, Szturmowicz M. Non-tuberculous mycobacterial lung disease (NTMLD) in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension. Pneumonol Alergol Pol. 2014;82(6):495–502. doi:10.5603/PiAP.2014.0066 Medline
• Zabost A, Augustynowicz-Kopeć E. Use of GenoType MTBDR plus assay for the detection of mycobacteria molecular rifampicin and isoniazid resistance. Post Nauk Med. 2015;4:249–254.

Identyfikatory

DOI

10.21307/pjm-2019-002